Travere Therapeutics Management
Management criteria checks 4/4
Travere Therapeutics' CEO is Eric Dube, appointed in Jan 2019, has a tenure of 6.75 years. total yearly compensation is $5.20M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $3.20M. The average tenure of the management team and the board of directors is 5 years and 8.5 years respectively.
Key information
Eric Dube
Chief executive officer
US$5.2m
Total compensation
| CEO salary percentage | 15.79% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval
Sep 10Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified
Sep 06
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt?
May 29
Expanded Approvals Will Broaden IgAN And FSGS Treatment Options
FILSPARI's expanded approval and ongoing studies position it for increased revenue from treating renal diseases, with potential market expansion from the new sNDA submission for FSGS.Revenues Working Against Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Following 26% Dive
Apr 11Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Mar 07Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts
Feb 14Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shareholders Might Be Looking For Exit
Feb 06Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Dec 19Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry
Oct 31Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Oct 07Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Sep 30Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$169m |
| Mar 31 2025 | n/a | n/a | -US$226m |
| Dec 31 2024 | US$5m | US$822k | -US$321m |
| Sep 30 2024 | n/a | n/a | -US$349m |
| Jun 30 2024 | n/a | n/a | -US$383m |
| Mar 31 2024 | n/a | n/a | -US$416m |
| Dec 31 2023 | US$8m | US$796k | -US$376m |
| Sep 30 2023 | n/a | n/a | -US$373m |
| Jun 30 2023 | n/a | n/a | -US$368m |
| Mar 31 2023 | n/a | n/a | -US$352m |
| Dec 31 2022 | US$6m | US$747k | -US$331m |
| Sep 30 2022 | n/a | n/a | -US$297m |
| Jun 30 2022 | n/a | n/a | -US$249m |
| Mar 31 2022 | n/a | n/a | -US$202m |
| Dec 31 2021 | US$6m | US$708k | -US$217m |
| Sep 30 2021 | n/a | n/a | -US$250m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$224m |
| Dec 31 2020 | US$5m | US$661k | -US$169m |
| Sep 30 2020 | n/a | n/a | -US$78m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$105m |
| Dec 31 2019 | US$10m | US$618k | -US$146m |
Compensation vs Market: Eric's total compensation ($USD5.20M) is about average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Dube (52 yo)
Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$5.20m | 0.15% $ 3.2m | |
| Chief Financial Officer | 3.2yrs | US$1.50m | 0.10% $ 2.3m | |
| Chief Research Officer | 8.7yrs | US$1.52m | 0.053% $ 1.2m | |
| Chief Commercial Officer | 6yrs | US$1.51m | 0.090% $ 2.0m | |
| Chief Medical Officer | 3.8yrs | US$1.68m | 0.10% $ 2.2m | |
| SVP, Corporate Controller & Chief Accounting Officer | 4.1yrs | no data | 0.061% $ 1.3m | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 8.8yrs | US$2.02m | 0.10% $ 2.2m | |
| Chief People Officer | no data | no data | no data | |
| Chief Business Officer | 1.8yrs | no data | no data | |
| Chief Corporate Affairs Officer | no data | no data | no data |
Experienced Management: TVTX's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$5.20m | 0.15% $ 3.2m | |
| Independent Director | 8.6yrs | US$242.32k | 0.040% $ 871.7k | |
| Independent Chairman of the Board | 11yrs | US$262.32k | 0.065% $ 1.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$242.32k | 0.032% $ 708.3k | |
| Independent Director | 9.3yrs | US$247.32k | 0.042% $ 924.0k | |
| Independent Director | 4.1yrs | US$234.82k | 0.029% $ 634.5k | |
| Independent Director | 10.6yrs | US$254.82k | 0.062% $ 1.4m | |
| Independent Director | 8.5yrs | US$237.32k | 0.040% $ 871.7k | |
| Independent Director | 11yrs | US$249.32k | 0.098% $ 2.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.4yrs | US$239.82k | 0.034% $ 739.3k |
Experienced Board: TVTX's board of directors are considered experienced (8.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:44 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Travere Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guyn Kim | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |
| Dae Gon Ha | BTIG |